The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina

Archives of Internal Medicine

Volumn 156, Issue 9, 1996, Pages 973-979

  Sullivan, Elizabeth A ^a   Kamb, Mary L ^a   Jones, Jeffrey L ^a,b   Meyer, Pamela ^b   Philen, Rossanne M ^a   Falk, Henry ^a   Sinks, Thomas ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b SOUTH CAROLINA DEPARTMENT OF HEALTH AND ENVIRONMENTAL CONTROL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRYPTOPHAN;

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG CONTAMINATION; EOSINOPHILIA MYALGIA SYNDROME; FEMALE; FOLLOW UP; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SCHOOL CHILD;

DRUG CONTAMINATION; EOSINOPHILIA-MYALGIA SYNDROME; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; TRYPTOPHAN;

EID: 0029942811     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.9.973     Document Type: Article

References (26)

1. Hertzman PA, Blevins WL, Mayer J, Greenfield B, Ting M, Gleich GJ. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med. 1990;322:869-873.
2. Swygert LA, Maes EF, Sewell LE, Miller L, Falk H, Kilbourne EM. Eosinophilia-myalgia syndrome: results of national surveillance. JAMA. 1990;264:1698-1703.
3. Centers for Disease Control. Eosinophilia-myalgia syndrome and L-tryptophan-containing products - New Mexico, Minnesota, Oregon, and New York. MMWR. 1989;38:785-788.
4. Philen RM, Eidson M, Kilbourne EM, Sewell M, Voorhees R. Eosinophilia-myalgia syndrome: a clinical case series of 21 patients. Arch Intern Med. 1991; 151:533-537.
5. Slutsker L, Hoesly FC, Miller L, Williams LP, Watson JC, Flemming DW. Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer. JAMA. 1990;264:213-217.
6. Belongia EA, Hedberg CW, Gleich GJ, et al. An investigation of the cause of eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med. 1990;323:357-365.
7. Back EE, Henning KJ, Kallenbach LR, Brix KA, Gunn RA, Melius JM. Risk factors for developing eosinophilia-myalgia syndrome among L-tryptophan users in New York. J Rheumatol. 1993;20:666-672.
8. Kamb ML, Murphy JJ, Jones JL, et al. Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients. JAMA. 1992;267:77-82.
9. Kamb ML, Jones JL, Kilbourne EM, Falk H. Eosinophilia-myalgia syndrome or fibromyalgia with eosinophilia? JAMA 1993;269:3108-3109.
10. National Center for Health Statistics. US Decennial Life Tables 1979-81 Volume II, State Life Tables Number 41, South Carolina. Washington, DC: US Dept of Health and Human Services; 1986. DHHS publication (PHS) 86-1151-41.
11. Wolfenden HH. On the methods of comparing the mortalities of two or more communities and the standardization of death rates. J R Stat Soc. 1923;86: 399-411.
12. SAS Institute Inc. SAS/STAT User's Guide, Release 6.03 Edition. Cary, NC: SAS Institute Inc, 1988.
13. Kaufman LD. Eosinophilia-myalgia syndrome: morbidity and mortality. J Rheumatol. 1993;20:1644-1645.
14. Junca J, Cuxart A, Tural C, Ojanguren I, Flores A. Eosinophilic fasciitis and non-Hodgkins lymphoma. Eur J Haematol. 1994;52:304-306.
15. Chan LS, Hanson CA, Cooper KD. Concurrent eosinophilis fasciitis and cutaneous T-cell lymphoma: eosinophilic fasciitis as a paraneoplastic syndrome of T-cell malignant neoplasms? Arch Dermatol. 1991;127:862-865.
16. Swygert LA, Back EE, Auerbach SB, Sewell LE, Falk H. Eosinophilia-myalgia syndrome: mortality data from the U.S. national surveillance system. J Rheumatol. 1993;20:1711-1716.
17. Hertz-Picciotto I, Neutra RR. Resolving discrepancies among studies: the influence of dose on effect size. Epidemiology. 1994;5:156-163.
18. Kircher T, Nelson J, Burdo H. The autopsy as a measure of accuracy of the death certificate. N Engl J Med. 1985;313:1263-1269.
19. McPhee SJ, Bottles K. Autopsy: moribund art or vital science? Am J Med. 1985;78:107-113.
20. National Center for Health Statistics. Advance report of final mortality statistics, 1991. Monthly Vital Stat Rep. 1993;42:12.
21. James JN, Kamb ML, Sandberg GA, Silver RM, Kilbourne EM. Postmortem studies of the heart in three fatal cases of eosinophilia-myalgia syndrome. Ann Intern Med. 1991;115:102-110.
22. Martin RW, Duffy J, Engel AG, Lie JT, Bowles CA, Mover TP, Gleich GJ. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion: clinical features in 20 patients and aspects of pathophysiology. Ann Intern Med. 1990;113:124-134.
23. Toxic Epidemic Syndrome Study Group. Toxic epidemic syndrome: Spain, 1981. Lancet. 1982;2:697-702.
24. Kilbourne EM, Rigau-Perez JG, Heath CW Jr, et al. Clinical epidemiology of toxic oil syndrome: manifestations of a new illness. N Engl J Med. 1983;309: 1408-1414.
25. Tabuenca JM. Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet. 1981;2:567-568.
26. Abaitua Borda I, Kilbourne EMS, Posada del la Paz M, Diez Ruis-Navarro M, Gabriel Sanchez R, Falk H. Mortality among persons affected by toxic oil syndrome: pilot study for retrospective follow-up of the cohort by mailed questionnaire. Int J Epidemiol. 1993;22:1077-1083.